Inhibitory Potential of Thelephoric Acid on CYP2J2 Activities in Human Liver Microsomes |
Wu, Zhexue
(College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, Boram (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Song, Kyung-Sik (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Liu, Kwang-Hyeon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) |
1 | Pucci, L., Lucchesi, D., Chirulli, V., Penno, G., Johansson, I., Gervasi, P., Del Prato, S. and Longo, V. 2003. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am J Pharmacogenomics 3, 355-358. DOI ScienceOn |
2 | Scarborough, P. E., Ma, J., Qu, W. and Zeldin, D. C. 1999. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31, 205-234. DOI ScienceOn |
3 | Shon, J. H., Yeo, C. W., Liu, K. H., Lee, S. S., Cha, I. J. and Shin, J. G. 2010. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J Clin Pharmacol 50, 195-204. DOI ScienceOn |
4 | Sun, J., Sui, X., Bradbury, J. A., Zeldin, D. C., Conte, M. S. and Liao, J. K. 2002. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90, 1020-1027. DOI ScienceOn |
5 | Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. E., Maxwell, B. D., Chen, S. Y., He, K., Goosen, T. C., Humphreys, W. G. and Grossman, S. J. 2010. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38, 448-458. DOI ScienceOn |
6 | Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R. and Zeldin, D. C. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271, 3460-3468. DOI |
7 | Yoon, Y. J. and Liu, K. H. 2011. Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome P450 2J2 isoform. J Korean Soc Appl Biol Chem 54, 659-666. DOI |
8 | Yu, Z., Huse, L. M., Adler, P., Graham, L., Ma, J., Zeldin, D. C. and Kroetz, D. L. 2000. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 57, 1011-1020. |
9 | Zeldin, D. C., Foley, J., Boyle, J. E., Moomaw, C. R., Tomer, K. B., Parker, C., Steenbergen, C. and Wu, S. 1997. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138, 1338-1346. DOI ScienceOn |
10 | Liu, K.-H. 2011. Screening of potential anticancer compounds from marketed drugs: aripiprazole, haloperidol, miconazole, and terfenadine inhibit cytochrome P450 2J2. J Life Sci 21, 1558-1564. 과학기술학회마을 DOI ScienceOn |
11 | Liu, K. H., Kim, M. G., Lee, D. J., Yoon, Y. J., Kim, M. J., Shon, J. H., Choi, C. S., Choi, Y. K., Desta, Z. and Shin, J. G. 2006. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34, 1793-1797. DOI ScienceOn |
12 | Park, J.-H., Wu, Q., Yoo, K.-H., Yong, H.-I., Cho, S.-M., Chung, I.-S. and Baek, N.-I. 2011. Cytotoxic effect of flavonoids from the roots of glycyrrhiza uralensis on human cancer cell lines. J Appl Biol Chem 54, 67-70. DOI ScienceOn |
13 | Makita, K., Takahashi, K., Karara, A., Jacobson, H. R., Falck, J. R. and Capdevila, J. H. 1994. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 94, 2414-2420. DOI ScienceOn |
14 | Matsumoto, S., Hirama, T., Kim, H. J., Nagata, K. and Yamazoe, Y. 2003. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33, 615-623. DOI ScienceOn |
15 | Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D. C. and Liao, J. K. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279. DOI ScienceOn |
16 | Pfister, S. L. and Campbell, W. B. 1996. Contribution of arachidonic acid metabolites to reduced norepinephrine-induced contractions in hypercholesterolemic rabbit aortas. J Cardiovasc Pharmacol 28, 784-791. DOI |
17 | Pfister, S. L., Spitzbarth, N., Zeldin, D. C., Lafite, P., Mansuy, D. and Campbell, W. B. 2003. Rabbit aorta converts 15-HPETE to trihydroxyeicosatrienoic acids: potential role of cytochrome P450. Arch Biochem Biophys 420, 142-152. DOI ScienceOn |
18 | Capdevila, J. H., Falck, J. R. and Harris, R. C. 2000. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41, 163-181. |
19 | Chen, C., Li, G., Liao, W., Wu, J., Liu, L., Ma, D., Zhou, J., Elbekai, R. H., Edin, M. L., Zeldin, D. C. and Wang, D. W. 2009. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 329, 908-918. DOI ScienceOn |
20 | Jiang, J. G., Chen, C. L., Card, J. W., Yang, S., Chen, J. X., Fu, X. N., Ning, Y. G., Xiao, X., Zeldin, D. C. and Wang, D. W. 2005. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65, 4707-4715. DOI ScienceOn |
21 | Jiang, J. G., Fu, X. N., Chen, C. L. and Wang, D. W. 2009. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng 28, 93-96. |
22 | Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., Yang, S., Zhou, J., Xiao, X., Zhang, X. A., Edin, M. L., Card, J. W., Wang, J., Zeldin, D. C. and Wang, D. W. 2007. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 67, 6665-6674. DOI ScienceOn |
23 | Lafite, P., Andre, F., Zeldin, D. C., Dansette, P. M. and Mansuy, D. 2007. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 46, 10237-10247. DOI ScienceOn |
24 | Lafite, P., Dijols, S., Buisson, D., Macherey, A. C., Zeldin, D. C., Dansette, P. M. and Mansuy, D. 2006. Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16, 2777-2780. DOI ScienceOn |
25 | Lee, C. A., Neul, D., Clouser-Roche, A., Dalvie, D., Wester, M. R., Jiang, Y., Jones, J. P., 3rd, Freiwald, S., Zientek, M. and Totah, R. A. 2010. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38, 347-356. DOI ScienceOn |
26 | Lee, S. S., Jeong, H. E., Liu, K. H., Ryu, J. Y., Moon, T., Yoon, C. N., Oh, S. J., Yun, C. H. and Shin, J. G. 2005. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 15, 105-113. DOI ScienceOn |